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OBJECTIF: étudier si les fluctuations sériques du taux d'hormone anti-müllérienne (AMH) sont 
liées à des différences méthodologiques entre les deux tests ELISA commercialement disponibles : 
le kit de Beckman Coulter Immunotech (Fullerton, CA) et le kit de Diagnostic Systems 
Laboratories (Webster, TX). 
DESIGN : étude prospective au sein de deux services universitaires de médecine de la 
reproduction. 
POPULATION ETUDIEE : cent soixante-huit échantillons sanguins provenant de trois 
populations différentes ainsi que des dosages itératifs au cours du même cycle menstruel dans une 
population de dix volontaires. 
INTERVENTIONS: doubles mesures en aveugle des taux sériques d' AMH dans les 168 sera avec 
les deux kits commercialement disponibles. Sept dosages itératifs au cours du même cycle 
menstruel chez 10 volontaires normo-ovulantes. 
ANALYSE STATISTIQUE: régression linéaire pour l'étude de la corrélation entre les deux 
méthodes de dosage. Analyse des variances pour les dosages sériés en cours de cycle menstruel. 
RESULTATS : nous avons démontré une relation linéaire entre les deux méthodes, avec un 
coefficient de corrélation de 0,88 ainsi qu'une diminution faible mais statistiquement significative 
et concomitante avec l'ovulation du taux d 'AMH sérique. 
CONCLUSION : les variations en cours de cycle menstruel rapportées par certains auteurs ne sont 
pas liées à des problèmes méthodologiques. La chute du taux d'AMH lors de l'ovulation est faible 
mais statistiquement significative. Les variations observées en cours de cycle restent toutefois 
inférieures aux variations intercycles et ne représentent de ce fait pas un obstacle au dosage de 
l' AMH à n'importe quel jour du cycle menstruel. 
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Objective: To investigate whether the controversy about fluctuations of anti-Müllerian hormone (AMH) levels dur-
ing the menstrual cycle results from differences between the immunoassays currently available: the Beckman 
Coulter Immunotech kit (Fullerton, CA) and the Diagnostic Systems Laboratories kit (Webster, TX). 
Design: Prospective trial. 
Setting: Fertility clinics of two tertiary university hospitals. 
Patient(s): One hundred sixty-eight blood samples from three different populations. Serial samples at set intervals 
from the LH surge were taken in a fourth population of IO volunteers. 
lntervention(s): We remeasured AMH levels by using the Diagnostic Systems Laboratories kit in 168 blood sam-
ples in which AMH initially had been measured by using the Beckman Coulter assuy. We also conducted serial 
AMH measurements (n = 7) during the menstrual cycle of IO women. 
Main Outcome Measure(s): Linear regression of AMH levels determined by using 2 different assuys und unulysis 
of variance of serial measurements in the menstruul cycle. 
Result(s): We found a linear relationship between the 2 methods, with a correlation coefficient of 0.88. When re-
peated individual AMH mensures were longitudinally analyzed in relation to the LH surge, a slight but significant 
decrease was observed after ovulation. 
Conclusion(s): Differences in AMH fluctuations during the menstruul cycle reported in recent publications do not 
result from the use of different AMH assays. The changes in AMH Ievels after ovulation are slight, yet statistically 
significant. However, the fluctuations observed are smaller than intercycle variability und therefore are not clini-
cally relevant as far as AMH measurements for clinical purposes are concerned. In daily practice, AMH therefore 
can be measured anytime during the menstrual cycle. (Fertil Steril® 2008; Il: 11-11. ©2008 by American Society 
for Reproductive Medicine.) 
Key Words: Anti-Müllerian hormone, AMH/MIS, menstrual cycle, contraception, Beckman Coulter assay, Diag-
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In recent years, it has been established that plasma anti-
Müllerian hormone (AMH) levels, which correlate with the 
number of antral and preantral follicles in mice (1), can be 
used for assessing ovarian reserve (2). Anti-Müllerian hor-
mone also has been proposed as a surrogate marker of the an-
tral follicular count (AFC) in polycystic ovary syndrome (3). 
One ofmost appealing advantages of AMH is that its levels 
have been shown to be stable under various influences such as 
hormonal contraception (4, 5), the menstrual cycle (5-7), and 
pregnancy (8), and measurements can therefore be made any-
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time during the menstrual cycle. Remarkably, in women 
affected by polycystic ovary syndrome, prolonged treatment 
with oral contraceptives, leading to a significant reduction of 
ovarian volume, did not modify AMH levels (5). Further 
supporting the contention that AMH is FSH independent 
(within the limits of FSH fluctuations encountered clinically), 
exogenous FSH administered to women who regularly ovulate 
(9) or have polycystic ovary syndrome (10) did not alter plasma 
AMH levels. Likewise, prolonged suppression of gonadotropins 
by GnRH-a failed to affect circulating levels of AMH (11). 
Contra~ting with the host of publications indicating that 
AMH levels are not affected by commonly encountered hor-
monal changes, two reports recently contended that AMH 
levels actually fluctuate during the menstrual cycle (12, 
13). These two studies therefore challenged the primary ad-
vantage of AMH, which, contrary to other markers of ovarian 
function such as FSH or inhibin B, could be measured at any 
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particular time. Of note, the two studies reporting changes in 
AMH levels during the menstrual cycle (12, 13) used the 
Diagnostic Systems Laboratories (DSL) (Webster, TX) kit, 
whereas all the publications showing no changes used the 
other commercially available assay, the Beckman Coulter 
Immunotech kit (BC) (Fullerton, TX) (5-7). 
We are aware of two publicly available studies that com-
pared AMH measurements obtained by using DSL and BC ul-
trasensitive assays (14, 15). Both studies observed important 
differences in AMH readings obtained with the two methods. 
The teams of Fréour et al. ( 14) and Bersinger et al. ( 15) inde-
pendently reported AMH results that were markedly lower, by 
factors of 4.6 and 3.1, when measured with the DSL kit as 
compared with the BC kit, respectively. Both groups con-
curred, however, in reporting that the two methods correlated 
well throughout the measuring range (14, 15). 
The reported differences between the DSL and BC assays 
cannot readily explain the fact that fluctuations in AMH 
levels were observed during the menstrual cycle only with 
one (DSL) but not the other assay (BC). Yet neither of the 
two available comparisons between the two assays was con-
ducted during the menstrual cycle. This therefore leaves 
unanswered questions about a possible role of the AMH as-
say in the existing controversy. Consequently, we queried 
whether methodological issues might have caused the differ-
ence observed during the menstrual cycle between the teams 
that used one (5-7) or the other kit ( 12, 13). This prompted us 
to conduct our own comparison. For this, we remeasured 
AMH by using the DSL kit in 168 serum specimens in which 
it previously had been measured with the BC method. We 
also measured serum AMH serially in IO women, at seven 
set intervals before and after the LH surge. 
MATERIALS AND METHODS 
To compare AMH measurements obtained using the two 
commercial ultrasensitive immunoassays currently available, 
BC and DSL, we remeasured AMH by using the DSL kit in 
168 blood samples in which AMH had already been mea-
sured with the BC method. These samples came from 95 
women in three different populations. 
Population 1 
This group included 24 young, ovulatory women. All were 
studied at two consecutive intercycle intervals (n = 24) and 
on day 16-18 and 23-25 of either the menstrual cycle (n = 
IO) or while receiving hormonal contraception orally (n = 
7) or vaginally (n = 7). Of96 samples, 1 was missing. Results 
from these 95 AMH measurements were the basis of an insti-
tutional review board-approved study published elsewhere 
by our team (5). 
Population 2 
This group included 58 individuals from a heterogeneous 
population, including women in whom AMH previously 
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had been measured during fertility workups at our institution 
between April 2005 and March 2007. Sampi es were 
randomly chosen in our blood bank, as part of quality-assess-
ment measures approved by our local institutional review 
board. 
Population 3 
Fifteen samples from 13 women, whose prior AMH measure-
ments were below the level that allows reliable detection with 
the BC method ( <0.4 ng/mL), also were included for remea-
surement with the DSL kit. This included four samples from 
two women who were the subject of a case report published 
by Fraisse et al. (16). 
Furthermore, we conducted a longitudinal analysis of 
repeated (n = 7) AMH measures in 10 healthy normally ov-
ulating volunteer women who had undergone a previous 
extensive assessment of the menstrual cycle. These evalua-
tions were approved by our institutional review board. Daily 
blood samples were available for each of these women. 
Recent publications elsewhere ( 12, 13) reporting fluctuations 
of AMH levels in the periovulatory period led us to measure 
AMH levels in these samples at time intervals around the LH 
surge. In each woman, AMH was measured in seven samples, 
at intervals before (LH-IO, -5, -2, and -1) and after the LH 
surge (LH + 1, +2, +IO), by using the BC kit only. 
All blood samples had been stored frozen at- l 8°C and 
were thawed only once for AMH measurement, using DSL 
(populations 1-3; n = 168) or BC (serial anal y sis in relation 
to the LH surge; n = 70). 
We analyzed AMH levels measured by using the two 
methods, BC and DSL, in study populations 1 and 2 by using 
linear regression analysis and Student's !-test. In our regres-
sion analysis, AMH DSL was defined as the independent var-
iable x, and AMH BC, as the dependent variable y. Statistical 
analysis was performed by using SPSS software version 14.0 
(SPSS, Inc., Chicago, IL). Power analysis was performed by 
using Medcalc version 9.3.1. Our study had a sufficient num-
ber of samples to show a correlation coefficient of 0.3 with 
a power of 0.8 and a type I error of 0.05. Levels of AMH in 
the menstrual cycle at seven intervals of the LH surge, con-
ducted in IO women, were analyzed by using analysis of 
variance for repeated measures. 
RESULTS 
In population 1, the regression equation of AMH by DSL 
over AMH by BC was y= 0.79 x + 3.24 ng/mL (Pearson's 
correlation coefficient r = 0.87; n = 95), indicating similar 
AMH results with the two assays (BC and DSL). Levels of 
AMH were in the range commonly encountered in female 
physiology (1.4-15 ng/mL). Changes in AMH levels mea-
sured by DSL that were observed during menstrual and hor-
monal contraception cycles were inferior to intercycle 
variability, as observed elsewhere by using the BC assay (4). 
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In population 2, AMH was measured in a heterogeneous 
population with a broader range of values, from 0.4 to 36 
ng/mL. The regression equation was as follows: y = 1.17 x 
+ 0.57 (Pearson's correlation coefficient, r = 0.98; n = 58). 
Results of populations 1 and 2 were subsequently re-
grouped, and a global regression was conducted for the 153 
measurements. Findings illustrated in Figure 1 show y = 
1.074 x -0.291 ng/mL where y = AMH BC and x = AMH 
DSL (Pearson's correlation coefficient, r = 0.88; n = 153). 
As illustrated, the results obtained with the BC and DSL 
AMH kits were similar (P=.81). 
In population 3, the DSL assay confirmed undetectable 
AMH levels in ail 15 samples, as previously observed with 
the BC assay, including in those oftwo women with an ongo-
ing pregnancy. 
Serum AMH levels measured with the BC kit in our serial 
analysis, conducted in the menstrual cycle at set intervals (n 
= 7) before and after the LH surge, were plotted in relation to 
the LH surge (Fig. 2). Analysis of variance revealed that 
AMH levels were significantly lower during the early luteal 
phase, as compared with early follicular-phase and late 
luteal-phase levels (Fig. 2; anal y sis of variance, P=.0159 
and P=.0197, respectively). 
DISCUSSION 
Our comparative analysis of 168 blood samples in which 
AMH was measured with DSL and BC ultrasensitive assays 
provided highly similar results. Our data therefore suggest 
that the differences between the studies that showed (12, 
13) or did not show (5, 6) fluctuations of AMH levels during 
the menstrual cycle using the DSL and BC assays, respec-
tively, are not rooted in methodological issues linked to the 
type of AMH assay used. 
In their report, Bersinger et al. (15) observed a lesser dif-
ference between AMH results obtained with the BC and 
DSL techniques than Fréour et al. (14) reported elsewhere. 
In the discussion of their results, Bersinger et al. ( 15) alluded 
to problems inherent to AMH measurements that stem from 
residual matrix effects and instabilities of certain antigenic 
determinants. Our current data, which resulted from mea-
surements that ail were conducted in 2007, failed to repoti 
any difference between serum AMH results obtained using 
BC or DSL assays. This therefore suggests that the above-
mentioned methodological problems have been addressed 
and solved by the assay manufacturers. 
In their report, Wunder et al. (12), using the DSL kit, ob-
served a statistically significant decrease in AMH levels, 
Fluctuation of AMH over the rnenstrual cycle in 10 healthy, norrnally ovulating volunteers (Beckrnan Coulter 
assay). 
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reaching a nadir in the early luteal phase. This pattern of 
changes in AMH levels parallels the description made by Lal-
hou et al. (13) and our current findings that were observed in 
10 patients who were serially sampled (n = 7) at set intervals 
before and after the LH surge (Fig. 2). Yet in ail cases, the fluc-
tuations in AMH levels were of small amplitude. In·our own 
study, the maximum mean upward and downward excursions 
of AMH levels were of +6% (95 % confidence interval, - 72 % 
to +85%) and -19% (95% confidence interval, -37% to 
+ 75% ), respectively, by reference to a mean value of 3.48 
ng/mL. The large confidence intervals are a consequence of 
the small sample size. In the Wunder et al. report (12), 
AMH fluctuated in the menstrual cycle between a mean max-
imum increase in the late follicular phase and a mean maxi-
mum decrease 4 days after the LH surge of +3% and 
-16%, respectively, by reference to a mean AMH value of 
3.19 ng/mL. In the abstract presentation of Lalhou et al. 
(13), the upward and downward excursions of AMH levels 
were of + 11 and -18%, respectively, by reference to 
a mean value of 3.29 ng/mL. In ail these studies, AMH fluctu-
ations, observed during the menstrual cycle above and below 
the mean value, were of the same or lesser amplitude than the 
intercycle variability of28% (95% confidence interval, -23.2 
to +80.3%) that we reported elsewhere (5). 
The pattern of AMH fluctuations in the menstrual cycle in-
dependently seen by us, Wunder et al. (12) and Lalhou et al. 
( 13) parallels the changes that Fanchin et al. (17) reported 
in controlled ovarian hyperstimulation cycles. Yet the fluctu-
ations observed in the menstrual cycle were of much smaller 
amplitude than those seen in controlled ovarian hyperstimula-
tion. These changes may reflect a decreased production of 
AMH by antral and preantral follicles and/or an abrupt reduc-
tion in the size ofthis cohort offollicles that would occur soon 
after ovulation. Theoretically, this follicular inhibition could 
result from direct adverse effects of the developing follicles 
and/or corpus luteum on the small preantral and antral folli-
cles. The observation that prolonged hormonal contraception 
in women with polycystic ovary syndrome failed to alter 
AMH levels despite a nearly 50% decrease in ovarian size 
(8) renders this latter explanation of changes in AMH levels 
during the menstrual cycle an implausible one, however. 
The mechanism of this slight periovulatory decrease in 
AMH levels has not yet been elucidated. A hypothesis could 
be the presence of one or more putative concealing mecha-
nisms interfering with the recognition of serum AMH after 
ovulation, thereby resulting in a false, rather than true, drop 
in AMH levels. This putative mechanism that accounts for 
the masking of AMH after ovulation could be the release of 
soluble AMH receptors into the blood circulation. In support 
of the hypothesis of a concealing phenomenon rather than 
a true drop is the rapid kinetic of the changes that has been ob-
served by us and others (12, 13). From our current understand-
ing of ovarian physiology, it is unlikely that the population of 
small preantral follicle changes in such a short time (18). Sim-
ilarly, the observation that changes in ovarian volume in re-
sponse to prolonged use of oral contraceptives failed to 
induce a change in AMH levels (4) speaks against a short-
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term change in AMH production by preantral follicles. How-
ever, the existence of this concealing factor remains unknown 
and could be the subject of future investigations. 
Our comparison of the results obtained by the BC and DSL 
assays also confirms the equal performance of these two 
assays at measuring very low AMH levels, including those 
below detection level (<0.4 ng/mL). Among the 15 low 
AMH samples, 4 came from two women who carried a nor-
mally developing pregnancy and who have been the abject 
of a case report (17). Remeasurement of AMH in these two 
women with the DSL kit confirmed AMH levels below detec-
tion lev el and indicated that the original finding ( 16) did not 
result from a methodological fluke. 
In conclusion, our results reveal that the two ultrasensitive 
assays for AMH measurements, BC and DSL, provide similar 
serum AMH results. Our results also confirm the slight 
changes in AMH levels reported by Wunder et al. (12) in 
the menstrual cycle. 
In ail three reports studying the periovulatory drop in 
AMH levels, the maximal fluctuations reported were smaller 
than or equal to the variability of AMH levels between two 
menstrual cycles shown in a report elsewhere (5). We there-
fore conclude that the fluctuations found in the early luteal 
phase are not greater than variations between two early follic-
ular phase measurements. Measurements of AMH performed 
in the early luteal phase consequently also can be used for 
clinical purposes. The results of our assay comparison there-
fore confirm that either the DSL or BC assay can be used to 
measure serum AMH, at any particular time during the men-
strual cycle or while taking either oral or vaginal hormonal 
contraception. 
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